Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis
NCT01380314
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Cutaneous Leishmaniasis
Interventions
DRUG:
Miltefosine + Imiquimod
DRUG:
Miltefosine 150 mg x day + Placebo
Sponsor
Foundation Fader